Researchers describe findings for targeted cancer therapies.
Stephenson
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects*; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008222:Lymphokines / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy; D011758:Pyrroles / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D007211:Indoles; D008222:Lymphokines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C116890:Semaxinib; D066246:ErbB Receptors; D000068818:Cetuximab